Clark Discusses Agility Clinical Acquisition With ClinicalOMICS
In the latest edition of ClinicalOMICS, Precision for Medicine President Chad Clark elaborates on the recent acquisition of rare and orphan CRO Agility Clinical. (more…)
Schafer Talks “One and Done” Gene Therapy Treatments With Managed Healthcare Executive
Tracy Walker from Managed Healthcare Executive talks with Precision for Value’s Jeremy Schafer regarding Kymriah, the first gene therapy approved for cancer treatment. (more…)
Precision for Medicine Acquires Leading Rare Disease CRO, Agility Clinical
Extending Precision’s Capabilities Into One of the Fastest Growing Areas of Drug Development
Bethesda, MD and Carlsbad, CA – September 6, 2017 – Precision for Medicine, part of the Precision Medicine Group, announced today it has acquired Agility Clinical (“Agility”), the leading contract research organization (CRO) focused specifically on clinical development of rare disease and orphan therapies. The acquisition creates the first comprehensive, fully integrated orphan therapy clinical development services provider, combining the highest standards in global clinical trial execution and biometrics expertise with sophisticated biomarker and specialty lab capabilities. (more…)
PHE’s Shafrin Defines Precision Medicine for US News & World Report
In a new commentary for US News & World Report, Precision Health Economics’ senior research economist Jason Shafrin defines and elaborates on the field of precision medicine. (more…)
Precision’s Leavitt in PM360: What to Do If Your Drug Is on the New Formulary Exclusion List
In a new article on PM360, Precision for Value executive vice president Bruce Leavitt provides step-by-step guidance for drug makers who find their product on one of the recently released formulary exclusion lists. (more…)